EPIX News and Press, ESSA Pharma Inc. From 11/18/21

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021 PR Newswire VANCOUVER, Canada and HOUSTON, Texas , Nov. 18, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company...

ESSA Pharma developed a novel mode of action drug, EPI-7386, for the treatment of metastatic castrate-resistant prostate cancer. Pre-clinical and early Ph 1 results are promising. ESSA's share price crashed in mid-Aug when a change in the Ph 1 trial protocol was announced, and a delay...

ESSA Pharma to Participate in Three Upcoming Investor Conferences Canada NewsWire VANCOUVER, Canada and HOUSTON, Texas , Nov. 8, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on d...

ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat Canada NewsWire VANCOUVER , Canada and HOUSTON , Texas , Oct. 28, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharm...

ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386 PR Newswire - Data presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics – VANCOUVE...

Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration PR Newswire IRVING, Texas , and HOUSTON, and VANCOUVER, BC , Oct. 7, 2021 /PRNewswire/ -- Caris Life Sciences ®, a molecular science company developing and de...

ESSA Pharma to Present at Upcoming September Investor Conferences PR Newswire VANCOUVER, Canada and HOUSTON, Texas , Aug. 31, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused...

ESSA Pharma (EPIX +7.6%) jumps 8%, as 10% owner, Biotech Growth NV buys 250,000 shares at the price of ~$8.87. This bring the owner's total share holding to ~5.02M shares. Recent news on the stock, 'ESSA Pharma at an eight-month low after delaying data read from prostate cancer tria...

Despite snapping a four-day rally on Wednesday, healthcare stocks in the S&P 500 gained for two consecutive sessions to end the week ~1.8% higher, outperforming the ~0.6% loss in the broader index. Among healthcare stocks with more than $300M market cap and over 100K averag...

Gainers: PharmaCyte Biotech (NASDAQ:PMCB) +118%. Virpax Pharmaceuticals (NASDAQ:VRPX) +59%. SGOCO Group (NASDAQ:SGOC) +53%. AzurRx BioPharma (NASDAQ:AZRX) +30%. NRx Pharmaceuticals (NASDAQ:NRXP) +26%. Standard Lithium (NYSE:SLI) +21%. ESSA Pharma (NASDAQ:EPIX) +15%. Agrify (NASDAQ:AGFY) +17%....